Interpace Biosciences Inc
OTC:IDXG
Intrinsic Value
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. [ Read More ]
The intrinsic value of one IDXG stock under the Base Case scenario is 6.46 USD. Compared to the current market price of 1.47 USD, Interpace Biosciences Inc is Undervalued by 77%.
Valuation Backtest
Interpace Biosciences Inc
Run backtest to discover the historical profit from buying and selling IDXG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Interpace Biosciences Inc
Current Assets | 11.4m |
Cash & Short-Term Investments | 5m |
Receivables | 4.8m |
Other Current Assets | 1.6m |
Non-Current Assets | 2.9m |
PP&E | 2.7m |
Other Non-Current Assets | 200k |
Current Liabilities | 12.3m |
Accounts Payable | 1.4m |
Accrued Liabilities | 8.9m |
Other Current Liabilities | 2m |
Non-Current Liabilities | 18.1m |
Long-Term Debt | 11.6m |
Other Non-Current Liabilities | 6.5m |
Earnings Waterfall
Interpace Biosciences Inc
Revenue
|
38.2m
USD
|
Cost of Revenue
|
-15.4m
USD
|
Gross Profit
|
22.8m
USD
|
Operating Expenses
|
-21.2m
USD
|
Operating Income
|
1.6m
USD
|
Other Expenses
|
-3.2m
USD
|
Net Income
|
-1.6m
USD
|
Free Cash Flow Analysis
Interpace Biosciences Inc
What is Free Cash Flow?
IDXG Profitability Score
Profitability Due Diligence
Interpace Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Interpace Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
IDXG Solvency Score
Solvency Due Diligence
Interpace Biosciences Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Interpace Biosciences Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDXG Price Targets Summary
Interpace Biosciences Inc
Ownership
IDXG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IDXG Price
Interpace Biosciences Inc
Average Annual Return | -5.65% |
Standard Deviation of Annual Returns | 91.05% |
Max Drawdown | -94% |
Market Capitalization | 6.3m USD |
Shares Outstanding | 4 320 000 |
Percentage of Shares Shorted | 1.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The firm has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
Contact
IPO
Employees
Officers
The intrinsic value of one IDXG stock under the Base Case scenario is 6.46 USD.
Compared to the current market price of 1.47 USD, Interpace Biosciences Inc is Undervalued by 77%.